GLP-1 receptor agonists such as semaglutide (marketed under brand names Ozempic, Wegovy, and Rybelsus) and the dual GIP/GLP-1 agonist tirzepatide (marketed under brand names Mounjaro and Zepbound) are FDA-approved prescription medications for specific uses in type 2 diabetes management and, in some cases, chronic weight management
For semaglutide (Wegovy), the typical starting dose is 0.25 mg weekly, with increases every four weeks until reaching the maintenance dose of 2.4 mg weekly (or 1.7 mg if the higher dose is not tolerated)
Our consistency system is worth reading around this point - it explains how habit formation actually works and why weeks 2-3 are where most people either lock it in or fall off
After propensity score matching, the analytic cohort comprised 26,408 matched patients: 13,204 users and 13,204 non-users
Retatrutide (LY3437943) is an investigational once-weekly injectable peptide developed by Eli Lilly that activates three key metabolic pathways simultaneously